



Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery

01/08/2025

\$20 Million Equity Investment from AMD Strengthens Absci's Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software

VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- [Absci Corporation](#) (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with [AMD](#) to deploy AMD Instinct™ accelerators and ROCm™ software to power critical AI drug discovery workloads, including Absci's advanced *de novo* antibody design models. AMD will also make a \$20 million investment in Absci, structured as a private investment in public equity (PIPE), underscoring the growing demand for innovative AI applications in drug discovery.

The strategic partnership supports Absci's mission of creating better biologics for patients, faster by providing optimized AI solutions for complex biological modeling that offer exceptional performance, reduced infrastructure costs, and faster innovation cycles. Absci Founder & CEO Sean McClain will discuss the strategic partnership at the 43rd Annual J.P.Morgan Healthcare Conference on Wednesday January 15th at 4:30pm PT. Absci and AMD will showcase the exceptional performance of AMD's Instinct accelerators in addressing complex biological applications, including Absci's proprietary IgDesign1 model, the first *in vitro* validated inverse folding model for antibody design.

"At Absci, we are always looking for ways to push the boundaries of what's possible in drug discovery," said Sean McClain, Founder & CEO of Absci. "This partnership with AMD gives us the unique advantage of working closely with a partner that is deeply committed to supporting our needs while providing the most efficient, innovative AI solutions available. AMD high-performance compute will enable us to further the development of next-generation antibody therapeutics, and we are excited about the potential that this partnership holds to accelerate the future of drug discovery."

"We are proud to partner with Absci, a company at the forefront of AI-driven drug discovery, to help further accelerate breakthroughs in therapeutics and transform how biologic drugs are developed," said Mark Papermaster, Executive Vice President and Chief Technology Officer of AMD. "Absci's groundbreaking work in AI drug discovery is a perfect fit for AMD high-performance computing solutions and software, designed for the most demanding AI workloads."

About Absci

[Absci](#) is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our [Integrated Drug Creation](#)™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci's headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn ([@absci](#)), X (Twitter) ([@Abscibio](#)), and [YouTube](#).

About AMD

For more than 50 years AMD has driven innovation in high-performance computing, graphics, and visualization technologies. Billions of people, leading Fortune 500 businesses, and cutting-edge scientific research institutions around the world rely on AMD technology daily to improve how they live, work, and play. AMD employees are focused on building leadership high-performance and adaptive products that push the boundaries of what is possible. For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ: AMD) [website](#), [blog](#), [LinkedIn](#) and [X](#) pages.

Absci Forward-Looking Statements

Certain statements in this press release that are not historical facts are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words "will," "may," "pursues," "anticipates," "plans," "believes," "aims," "potential," "forecast," "estimates," "extends," "expects," and "intends," or similar expressions. Absci intends these forward-looking statements, including express or implied statements regarding acceleration of the future of AI drug discovery, Absci's leadership in AI drug discovery, Absci's ability to leverage AMD's equity investment, and Absci's ability to create better biologics and develop next generation antibody therapeutics, among others, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and Absci makes this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect Absci's current views about its plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to it and on assumptions Absci has made. Absci can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond Absci's control, including, without limitation, risks and uncertainties relating to Absci's ability to leverage AMD's investment, effectively collaborate on research, drug discovery and development activities with its partners or potential partners, Absci's dependence on third parties to support its internal development programs, including for the manufacture and supply of preclinical and clinical supplies of its product candidates or components thereof, its existing and potential partners' ability and willingness to pursue the development and commercialization of programs or product candidates under the terms of Absci's partnership agreements, and overall market conditions and regulatory developments that may affect Absci's and its partners' activities under these agreements, along with those risks set forth in Absci's most recent periodic reports filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, Absci assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.

Absci Investor Contact
Alex Khan
VP, Finance & Investor Relations

investors@absci.com

Absci Media Contact

press@absci.com

Investor Relations:

Matt Ramsay

AMD Investor Relations

Matthew.Ramsay@amd.com

AMD Media Contact

Brandi Martina

AMD Communications

brandi.martina@amd.com